Akut Radyasyon Sendromunda Hematopoetik Sendromu ve Terapötik Yaklaşım
Özet
Akut Radyasyon Sendromu (ARS), tüm vücudun veya büyük bir kısmının yüksek dozda iyonlaştırıcı radyasyona maruz kalmasıyla gelişen ölümcül bir tablodur. Sendromun en erken ve kritik komplikasyonlarından biri olan Hematolojik Sendrom, radyasyonun kemik iliğindeki pluripotent hematopoetik kök hücreleri doğrudan hasara uğratması ve apoptoza yol açması sonucu ortaya çıkar. Bu süreç, hücre bölünme kapasitesinin sınırlanmasıyla kanda aplastik anemi ve derin sitopenilere zemin hazırlar. Klinik seyir; maruziyetten hemen sonra grip benzeri semptomların görüldüğü prodromal faz, laboratuvarda hücre düşüşünün başladığı ancak kliniğe yansımadığı gizli faz ve ardından derin sitopenilerin açıkça belirdiği hastalık fazı olarak ilerler. Açık hastalık döneminde hastada lenfosit ve nötropeni düşüşüne bağlı ölümcül enfeksiyonlar, trombositopeniye bağlı durdurulamayan kanamalar ve ağır anemiye bağlı çoklu organ yetmezliği gelişebilir. Tanı klinik öykü ve sık hemogram takibiyle konulur; özellikle lenfosit sayısı ilk kritik göstergedir. Tedavide G-CSF (filgrastim, pegfilgrastim) gibi sitokinler kemik iliği iyileşmesini uyarmak için kullanılırken, derin sitopenilerde lökositi azaltılmış ve irradiye edilmiş transfüzyon destekleri uygulanır. İki haftayı geçen dirençli pansitopeni vakalarında kök hücre nakli seçeneği değerlendirilir ve enfeksiyonlara karşı geniş spektrumlu proflaktik antibiyotik tedavisi ivedilikle başlanır.
Acute Radiation Syndrome (ARS) is a life-threatening condition resulting from acute exposure of a major part of the body to high doses of ionizing radiation. Hematological syndrome is one of its earliest manifestations, caused by direct damage to pluripotent hematopoietic stem cells in the bone marrow, leading to aplasia and apoptosis. This bone marrow depletion restricts cell division capacity and results in radiation-induced aplastic anemia and severe peripheral cytopenias. Clinically, ARS progresses through four phases: the prodromal phase with early flu-like symptoms; the latent phase where blood counts decline without clinical symptoms; the manifest illness phase; and recovery or death. During manifest illness, profound lymphopenia and neutropenia lead to opportunistic infections, thrombocytopenia causes severe hemorrhages, and anemia results in tissue hypoxia. Diagnosis relies on clinical history and rigorous blood count monitoring, with lymphocyte depletion serving as a key early indicator. Management involves administering cytokines like G-CSF (filgrastim, pegfilgrastim) to stimulate marrow recovery, alongside irradiated transfusion support. For persistent pancytopenia lasting over two weeks, stem cell transplantation is considered, and broad-spectrum prophylactic antibiotics are initiated to counter neutropenic fever.
Referanslar
Fauci AS, Braunwald E, Kasper DL, et al, editors. Radiation injury. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill Professional; 2008;2559–2568.
Heslet L, Bay C, Nepper-Christensen S. Acute radiation syndrome (ARS)–treatment of the reduced host defense. International journal of general medicine. 2012;5:105.
Ricks RC, Berger ME, O'Hara Jr FM, editors. The medical basis for radiation-accident preparedness: the clinical care of victims. CRC Press; 2002.
Cohen KS, Gusev I, Guskova A, et al. Medical management of radiation accidents. CRC Press; 2001.
Jarrett D. Medical management of radiological casualties handbook. Armed Forces Radiobiology Research Inst Bethesda MD; 1999.
Chinnadurai R, Forsberg MH, Kink JA, et al. Use of MSCs and MSC-educated macrophages to mitigate hematopoietic acute radiation syndrome. Current Stem Cell Reports. 2020;1-9.
Rubin P, Constinc LS, Williansıs JP. Late affects of cancer treatment: Radiation and drug toxicity. In Perez CA, Brady LW (eds). Principles and Practice of Radiation Oncology. Lippicoil-Raven, Philadelphia, 1998;155-213.
Anno GH, Young RW, Bloom RM, et al. Dose response relationships for acute ionizing-radiation lethality. Health physics. 2003;84(5):565-75.
McCann, D.G.C. Radiation poisoning: current concepts in the acute radiation syndrome. Am. J. Clin. Med. 2006;3:13–21.
Waselenko JK, MacVittie TJ, Blakely WF, et al. Strategic National Stockpile Radiation Working Group: Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med. 2004;140(12):1037-51.
LaTorre Travis E. Primer of Medical Radiobiology. Year Book Medical Publishers. 1989.
Brodsky RA, Jones RJ. Aplastic anaemia. The Lancet. 2005;365(9471):1647-56.
Beutler ER, Lichtman MA, Coller BS, et al. Approach to the Patient. Williams Hematology. 6th edition. New York: McGraw Hill. 2001:3-8.
National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0
Gorin NC, Fliedner TM, Gourmelon P, et al. Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol 2006;85:671.
Dainiak N, Gent RN, Carr Z, et al. First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. Disaster Med Public Health Prep 2011;5:202.
Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol. 2002;30:513-28.
Hall EJ. Acute effects of total-body irradiation. In: Hall EJ. Radiobiology for the Radiologist. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2000;124-35.
van Bekkum DW. Radiation sensitivity of the hemopoietic stem cell. Radiat Res. 1991;128:S4-8.
Inoue T, Hirabayashi Y, Mitsui H, et al. Survival of spleen colony-forming units (CFU-S) of irradiated bone marrow cells in mice: evidence for the existence of a radioresistant subfraction. Exp Hematol. 1995;23:1296-300.
Vorobiev AI. Acute radiation disease and biological dosimetry in 1993. Stem Cells. 1997;15(S1):269-74.
Mandel NM, Onat H. Kanser Hastasına Yaklaşım. Tanı, Tedavi, Takipte Sorunlar. Bölüm 43; Radyoterapiye Bağlı Geç Yan Etkiler. Nobel Tıp Kitapevi 2. Baskı. 2012; 429-39.
Flynn DF, Goans RE. Nuclear terrorism: triage and medical management of radiation and combined-injury casualties. Surgical Clinics. 2006;86(3):601-36.
Gusev IA, Guskova AK, Mettler FA Jr, editors. Medical Management of Radiation Accidents, 2 nd ed., New York : CRC Press, Inc.; 2001.
Centers for Disease Control and Prevention (CDC). CDC 24/7; Saving Lives, Protecting PeopleTM. Radiation Emergencies. Acute Radiation Syndrome: A Fact Sheet For Clinicans. [Avaible from: https://www.cdc.gov/nceh/radiation/emergencies/arsphysicianfactsheet.htm]
Donnelly EH, Nemhauser JB, Smith JM, Kazzi ZN, Farfán EB, Chang AS, Naeem SF. Acute radiation syndrome: assessment and management. Southern medical journal. 2010;103(6):541-6.
Wright CR, Ward AC, Russell AP. Granulocyte colony-stimulating factor and its potential application for skeletal muscle repair and regeneration. Mediators Inflamm 2017;2017:7517350.
U.S. Food & Drug Administration. Guidances (Drugs).
Dainiak N. Rationale and recommendations for treatment of radiation injury with cytokines. Health physics. 2010;98(6):838-42.
Smith TJ, Bohlke K, Armitage JO. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology clinical practice guideline update. Journal of oncology practice. 2015;11(6):511-3.
National Comprehensive Cancer Network (NCCN) Hematopoietic Growth Factors Version 4.2021- May 20, 2021. [Avaible from: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf]
Zaja F, Barcellini W, Cantoni S, et al. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. American journal of hematology. 2016;91(5):E293-5.
Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. New England Journal of Medicine. 2017;376(16):1540-50.
HĂŠrodin F, Mourcin F, Drouet M. Which place for stem cell therapy in the treatment of acute radiation syndrome?. Folia histochemica et cytobiologica. 2005;43(4):223-7.
National Organisation for Rare Disorders (NORD). Radiation Sickness. [Avaible from: https://rarediseases.org/rare-diseases/radiation-sickness/]
Singh VK, Seed TM. Entolimod as a radiation countermeasure for acute radiation syndrome. Drug Discovery Today. 2020.
Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320(5873):226-30.
Krivokrysenko VI, Toshkov IA, Gleiberman AS, et al. The Toll-like receptor 5 agonist entolimod mitigates lethal acute radiation syndrome in non-human primates. PloS one. 2015;10(9):e0135388.
